<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527019</url>
  </required_header>
  <id_info>
    <org_study_id>EF125</org_study_id>
    <nct_id>NCT01527019</nct_id>
  </id_info>
  <brief_title>Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)</brief_title>
  <acronym>CECI</acronym>
  <official_title>A Phase III Non-Inferiority Open-label Multicenter Randomized Clinical Trial to Compare CEPHALOSPORIN to NORFLOXACIN in the Treatment of Acute Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess if the efficacy of cephalosporin is similar to the efficacy of&#xD;
      norfloxacin in the acute cystitis treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    the company suspended the persecution of this combination&#xD;
  </why_stopped>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteriological Eradication</measure>
    <time_frame>5-9 days</time_frame>
    <description>The primary endpoint of this study will be the bacteriological eradication rate obtained 5-9 days following the end of the treatment with study drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>bacteriological eradication rate 4-6 weeks; clinical cure rate 5-9 days; clinical cure rate 4-6 weeks;uroculture 5-9 days and 4-6 weeks</time_frame>
    <description>To determine the bacteriological eradication rate 4-6 weeks after the end of treatment; To determine the clinical cure rate 5-9 days after the end of treatment; To determine the clinical cure rate 4-6 weeks after the end of treatment; To determine the clinical cure rate for research subjects with negative uroculture 5-9 days and 4-6 weeks after the end of treatment; To assess the research subjects adherence to the study treatment; To assess the safety of antibiotics according to the incidence of adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cystitis</condition>
  <arm_group>
    <arm_group_label>Cephalosporin oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>130 research subjects on cephalosporin oral suspension (test) 400 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalosporin capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>130 research subjects on cephalosporin capsules (test) 400 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norfloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>130 research subjects on norfloxacin (test) 400 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)</description>
    <arm_group_label>Norfloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalosporins</intervention_name>
    <description>Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)</description>
    <arm_group_label>Cephalosporin capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalosporins</intervention_name>
    <description>Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)</description>
    <arm_group_label>Cephalosporin oral suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign, initialize and date the informed consent form&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  For urinary infection diagnosis, the following parameters must be considered in the&#xD;
             urine I test:&#xD;
&#xD;
          -  Leukocyturia: ≥ 15,000 leukocytes&#xD;
&#xD;
          -  Epidermal cells: &lt; 20,000/mL&#xD;
&#xD;
          -  Presence of bacteriuria&#xD;
&#xD;
          -  Presence of nitrite (positive results)&#xD;
&#xD;
          -  To have a 2 points score (from 12 points) regarding the following symptoms of acute&#xD;
             cystitis:&#xD;
&#xD;
          -  Dysuria&#xD;
&#xD;
          -  Urinary urgency&#xD;
&#xD;
          -  Frequent urination&#xD;
&#xD;
          -  Pain in the upper area of pubis&#xD;
&#xD;
        Each symptom must be scored according to the classification below. Total score may range&#xD;
        from 0 to 12 points.&#xD;
&#xD;
        Severity Value Absent 0 Mild 1 Moderate 2 Severe 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Research subjects that meet any of the criteria below will not be eligible for the study:&#xD;
&#xD;
          -  Asymptomatic urinary infection or infection in any organ&#xD;
&#xD;
          -  Documented incidence of UTI in the last year&#xD;
&#xD;
          -  Symptoms of pyelonephritis (cystitis symptoms plus fever, lower back pain or chills)&#xD;
&#xD;
          -  History of complicated urinary tract infection (congenital abnormalities, urinary&#xD;
             tract distortion or obstruction, formation of calculus in the urinary tract)&#xD;
&#xD;
          -  Use of catheter in the urinary tract&#xD;
&#xD;
          -  Chronic renal or hepatic disease&#xD;
&#xD;
          -  Seizure-related diseases&#xD;
&#xD;
          -  Neurological deficits that interfere in the urinary flow and tract defense&#xD;
&#xD;
          -  Decompensated diabetes mellitus (fasting blood glucose ≥ 150 mg/dL);&#xD;
&#xD;
          -  Immunodepression:&#xD;
&#xD;
          -  Subjects with the human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Chronic use of corticosteroids in a dose ≥ 5 mg/day of prednisone for over 30 days&#xD;
&#xD;
          -  Any diseases related to immune dysfunction&#xD;
&#xD;
          -  Severe comorbidities (at the investigator's discretion)&#xD;
&#xD;
          -  History of allergy to penicillins, cephalosporines or quinolones&#xD;
&#xD;
          -  Subjects on medications such as antibiotics, amiodarone, antacids or sucralphate,&#xD;
             tricyclic antidepressants, antipsychotics, cyclosporine, cisapride, didanosine,&#xD;
             erythromycin, fembufeno, gliburide (a sulphonilurea), nitrofurantoin, probenecid,&#xD;
             procainamide, quinidine, sotalol, teophylline, warfarin&#xD;
&#xD;
          -  Treatment due to UTI two weeks before entering study, or on antimicrobial treatment at&#xD;
             least 3 times within the last 12 months&#xD;
&#xD;
          -  Use of phenazopyridine 7 days before entering the study&#xD;
&#xD;
          -  Hospitalization 30 days before study enrollment&#xD;
&#xD;
          -  Female research subjects that are pregnant, breastfeeding, or women with childbearing&#xD;
             potential that deny to use at least two safe contraceptive methods during study&#xD;
&#xD;
          -  Participation in another clinical trial in the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Cystitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

